Xiidra Solution/ Drops
Product Images NDC 0078-0911

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Xiidra (NDC 0078-0911). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xiidra 01)

Chemical structure of lifitegrast, the active ingredient in Xiidra 50 mg/mL ophthalmic solution. The diagram depicts the molecular configuration including heterocyclic rings, chlorine atoms, and functional groups consistent with lifitegrast's chemical formula.*

FDA Label Image

Figure 1 (Xiidra 02)

Four separate forest plots from clinical studies comparing the ophthalmic solution Xiidra (Lifitegrast) to vehicle controls over multiple visits. Each plot shows mean values and confidence intervals for baseline, Day 14, Day 42, and Day 84 visits, with the difference between Xiidra and vehicle indicating favored outcomes for Xiidra across all studies.*

FDA Label Image

Figure 2 (Xiidra 03)

This image shows four forest plot graphs from separate studies comparing vehicle versus Xiidra (lifitegrast) ophthalmic solution. Each plot presents mean differences with 95% confidence intervals at baseline, day 14, day 42, and day 84 visits, illustrating the treatment effect favoring Xiidra. The x-axis ranges from -0.50 to 0.25, with markers indicating the direction and magnitude of effect for each time point.*

FDA Label Image

Figure A (Xiidra 04)

An instructional diagram showing two hands holding a sealed packet, with one hand peeling back a tear strip to open it. The image demonstrates how to open the packet, likely intended for single-use ophthalmic solution packaging such as Xiidra 50 mg/mL drops by Novartis Pharmaceuticals Corporation.*

FDA Label Image

Figure B (Xiidra 05)

A black and white line drawing showing a hand holding a single small unit-dose vial of ophthalmic solution, with four additional vials lined up beside it. Each vial has a sealed cap and vented neck for dispensing drops, representing the packaging style for a drop solution product.*

FDA Label Image

Figure C (Xiidra 06)

An instructional line drawing showing a pair of hands opening a foil packet containing three single-use vials or ampules, likely for an ophthalmic solution. The image illustrates the removal of individual vials from packaging, typically used for single-dose administration.*

FDA Label Image

Figure D (Xiidra 07)

An illustration showing two hands holding and preparing to open a small sealed pouch, likely for single-use ophthalmic solution drops. The drawing focuses on the technique to open the packet safely.*

FDA Label Image

Figure E (Xiidra 08)

An instructional illustration showing a hand holding a single-dose container of Xiidra (Lifitegrast) ophthalmic solution 50 mg/mL. The image demonstrates proper grip of the small vial, likely for administration of the eye drops.*

FDA Label Image

Figure F (Xiidra 09)

An instructional illustration showing a person holding a small ophthalmic solution vial with one hand while using the index finger of the other hand to snap or break off the vial's top.*

FDA Label Image

Figure G (Xiidra 10)

An instructional illustration showing a pair of hands demonstrating how to open a single-use ophthalmic solution vial, likely for Xiidra (Lifitegrast) 50 mg/mL solution drops. The image indicates twisting the cap off the small plastic vial before use.*

FDA Label Image

Figure H (Xiidra 11)

An instructional line drawing showing a person tilting their head back and using one hand to drop ophthalmic solution into the eye, while the other hand gently pulls down the lower eyelid to create a pouch for the drops.*

FDA Label Image

Principal Display Panel Ndc 0078-0911-12 Xiidra® (Xiidra 12)

Xiidra (lifitegrast) ophthalmic solution 5%, 60 single-use containers in 12 pouches. Each single-use container is 0.2 mL. The packaging label is predominantly blue and white with the Novartis Pharmaceuticals Corporation logo. This product is for topical application to the eye and is designated Rx Only. The NDC 0078-0911-12 is visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.